- Home
- DUK vs GSK Comparison
DUK vs GSK Comparison
Compare DUK & GSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$121.95
HOLD
Current Price
$51.71
Company Overview
Basic Information| Metric | DUK | GSK |
|---|---|---|
| Founded | 1904 | 1715 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Railroads | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.3B | 108.7B |
| IPO Year | 2006 | 2013 |
Fundamental Metrics
Financial Performance| Metric | DUK | GSK |
|---|---|---|
| Price | $121.95 | $51.71 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 2 |
| Target Price | ★ $137.40 | N/A |
| AVG Volume (30 Days) | ★ 4.5M | 3.8M |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | 3.37% | ★ 3.40% |
| EPS Growth | ★ 10.51 | N/A |
| EPS | ★ 1.97 | N/A |
| Revenue | ★ $19,624,000,000.00 | N/A |
| Revenue This Year | $5.57 | $6.99 |
| Revenue Next Year | $4.18 | $4.19 |
| P/E Ratio | $60.84 | ★ $32.75 |
| Revenue Growth | ★ 35.07 | N/A |
| 52 Week Low | $113.90 | $38.63 |
| 52 Week High | $134.49 | $61.70 |
Technical Indicators
Market Signals| Indicator | DUK | GSK |
|---|---|---|
| Relative Strength Index (RSI) | 42.51 | 50.00 |
| Support Level | $120.46 | $51.55 |
| Resistance Level | $125.74 | $51.79 |
| Average True Range (ATR) | 2.08 | 0.81 |
| MACD | -0.28 | 0.10 |
| Stochastic Oscillator | 35.81 | 65.20 |
Price Performance
Historical Comparison DUK
GSK
About DUK Duke Energy Corporation (Holding Company)
Duke Energy is one of the largest US utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to more than 8 million customers. Its natural gas utilities serve more than 1.6 million customers.
About GSK GSK plc (Each representing two)
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.